Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine injection vs haloperidol for acute agitation in schizophrenia or bipolar I disorder
CTR20230808Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in schizophrenia, bipolar I disorder, agitation (acute), sponsored by Qilu Pharmaceutical. Started Mar 2023; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniabipolar I disorderagitation (acute)
Beyond the preview
Go deeper on CTR20230808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230808.